Topics

Amgen Inc.
Amgen reports positive results from analysis of its blood cancer drug
Amgen reports positive results from analysis of its blood cancer drug

Biotech giant Amgen Inc. said a preliminary analysis of its prized blood cancer drug showed patients who took it fared better than those using the standard treatment. The Thousand Oaks company said that patients with relapsed multiple myeloma who took the Kyprolis drug, along with two other therapies, lived 8.7 months longer without their blood cancer worsening than if they took the standard treatment. Multiple myeloma is the second-most-common blood cancer, affecting about 70,000 people in the United States, Amgen said. Amgen gained the coveted blood cancer drug last year when it acquired Onyx Pharmaceuticals Inc. for $10.4 billion. The FDA granted an accelerated, preliminary approval...

Loading